Profil
Currently, Kean Meng Toh is Executive Director, Chief Scientific Officer & VP at CK Life Sciences International (Holdings), Inc. since 2018, and Director at Dogwood Therapeutics, Inc. since 2024.
Formerly, Dr. Toh was Director at Virios Therapeutics, Inc. Education includes undergraduate and doctorate degrees from the National University of Singapore and a graduate degree from the University of London.
Postes actifs de Kean Meng Toh
| Sociétés | Poste | Début |
|---|---|---|
| CK LIFE SCIENCES INT'L., (HOLDINGS) INC. | Directeur Technique/Scientifique/R&D | 15/11/2018 |
Anciens postes connus de Kean Meng Toh
| Sociétés | Poste | Fin |
|---|---|---|
Virios Therapeutics, Inc.
Virios Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products for fibromyalgia and other related conditions | Directeur/Membre du Conseil | - |
Formation de Kean Meng Toh
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 4 |
|---|---|
Virios Therapeutics, Inc.
Virios Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products for fibromyalgia and other related conditions | Health Technology |
CK Life Sciences International (Holdings), Inc.
CK Life Sciences International (Holdings), Inc. Pharmaceuticals: OtherHealth Technology Manufactures and markets pharmaceuticals, agriculture and nutraceuticals products | Health Technology |
National University of Singapore
National University of Singapore Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of London
University of London Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
















